Navigation Links
The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development
Date:7/23/2014

really an illusion created by two limitations. First, the stem cells that are most readily obtained and multiplied are mesenchymal stem cells (MSCs), which are found in tissues like fat, bone marrow, skin, and joints, but are not the primary stem cells that form many of the organs and tissues in need of regenerative medicine treatments (e.g., pancreas, heart, nerves, liver). Second, although much research has been conducted with MSCs, what they might accomplish in human patients after heterologous transplantation can only be learned by conducting high-quality clinical trials.

Whether or not heterologous stem cell transplantation therapy, with all of its noted reservations, proves beneficial, extending homologous regenerative therapies – like bone marrow stem cell transplantation – to more organs and tissues is an important regenerative medicine goal. Contributing to achieving this goal is the core business of Boston’s ASCTC.

The ASCTC recently announced the approval of a new patent for producing induced pluripotent stem cells more efficiently. The new patent has a foundation in the ACSTC’s portfolio of patents for methods to multiply adult stem cells from diverse organs and tissues that are important targets for regenerative medicine therapies.

The lead adult stem cell expansion technology currently pursued by the company is for human liver adult stem cells. Produced in sufficient quantity, human liver stem cells could be used to produce functionally mature human liver cells called hepatocytes. Hepatocytes are essential for drug testing before advancing to clinical drug trials with patients. Current sources of these cruci
'/>"/>

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. American Botanical Council Publishes a History of Adulteration
2. China Sky One Medical to Jointly Launch Adult Stem Cell Research Enterprise
3. Nonprofit Consortium Publishes Review of Skullcap Adulteration
4. BioRestorative Therapies Announces Closing of License Agreement for Adult Stem Cell Disc/Spine Procedure
5. Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood
6. NIH media availability: Protein linked to increased risk of heart failure and death in older adults
7. StemGenex to Launch Adult Stem Cell-Based Therapy to Relieve COPD Symptoms
8. Some Bilberry Fruit Extracts Adulterated, says Nonprofit Research Consortium
9. Thackray Crane Rental Prepares Visible Memorial For The Newtown, Connecticut Children and Adults Who Were Ambushed and Taken Away From Their Families
10. Adult Stem Cell Therapy Breakthrough Leads to Crowd Funding Campaign on Indiegogo.com for Centagen, Inc.
11. Island Abbey Foods Ltd™ Now Offering New Honibe® Honey Lozenges™ Flavour Variations for Both Adults and Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was ... Pre-Conference seminar on probiotics in San Diego, CA. , ... conference for health care professionals. This year’s pre-conference seminar was ... in health. Dr. Leyer spoke about the emerging topics and ...
(Date:1/22/2015)...   Cypher Genomics, Inc., the leading genome ... SQNM ), the leading molecular diagnostics company, today ... prenatal tests (NIPT). Through this agreement, Sequenom will ... advance analysis of clinically-relevant fetal sub-chromosomal variants detected ...
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... St. Louis, Missouri (PRWEB) December 23, 2014 ... Swiss biotechnology company, Syngenta, are in the process of being ... consolidated case is In Re: Syngenta AG MIR 162 Corn ... the District of Kansas. , Management of the Syngenta GMO ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... 18 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... authorization (CTA) for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), ... Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome, ... Healthcare Products Regulatory Agency (MHRA). BioMarin expects to initiate ...
... Inc. (OTC Bulletin Board: CSBR), a company engaged in ... data to enhance the value of oncology drugs, reports ... January 31, 2009. Full details of the Company,s ... at www.championsbiotechnology.com . Total revenues for the third ...
... forces), used by ergonomic engineers worldwide, is now more versatile and ... capacities have been doubled to accurately measure up to 300 lbs. ... ... 2009 -- HOGGAN Ergo, Ergonomic Division of HOGGAN Health Industries, ...
Cached Biology Technology:BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 3BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 4Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 5Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 6HOGGAN Ergo Announces Highly Anticipated Enhancements to the ergoFET Handheld Digital Force Gauge, Greatly Impacting the Field of Ergonomic Research and Application 2HOGGAN Ergo Announces Highly Anticipated Enhancements to the ergoFET Handheld Digital Force Gauge, Greatly Impacting the Field of Ergonomic Research and Application 3
(Date:1/22/2015)... ROBERTS, Washington , January 20, 2015 ... and tech stocks, releases video from the CES 2015 (Consumer ... consultant Apollo Robbins . Apollo shows how ... biometric smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
(Date:1/22/2015)... EyeLock, Inc. , a market leader of iris-based identity authentication ... to the new role of Senior Vice President of Mobile ... mobile platforms and wearable solutions for EyeLock,s technologies. Gerber brings ... semiconductor industry to his role at EyeLock, with expertise in ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ... "The Global Watermarking and Fingerprinting Markets" report ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides an ... fingerprinting markets. Watermarking aims to control and monitor ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2The Global Watermarking and Fingerprinting Markets 2
... Like their human hosts, bacteria need iron to survive and ... obtain iron primarily through the food they eat, bacteria have ... iron. A Syracuse University research team led by Robert ... and Sciences, discovered that some bacteria are equipped with a ...
... to achieve normal levels of blood sugar in ... levels. If this approach succeeds in humans, it ... congenital hyperinsulinism, a rare but potentially devastating genetic ... "There is currently no effective medical treatment ...
... the lowliest bacterium use molecules to communicate. Some chemicals ... still others are used to attract members of the ... have now found a rare kind of signaling molecule ... serves a dual purpose, working as both a population-control ...
Cached Biology News:Syracuse University scientists discover how some bacteria may steal iron from their human hosts 2Syracuse University scientists discover how some bacteria may steal iron from their human hosts 3Treatment corrects severe insulin imbalance in animal studies 2Treatment corrects severe insulin imbalance in animal studies 3Caltech researchers find dual-use sexual attraction and population-control chemicals in nematodes 2Caltech researchers find dual-use sexual attraction and population-control chemicals in nematodes 3
... Automatic High Sensitivity Laboratory Osmometer for both 0.2 and 2.0 mL samples for ... and record keeping. Bar code reading capability with optional scanner. RS-232 port. ... ... ...
MAb to Hu-IFN-Gamma RC2 (CD118), NON-Neutralizing, Clone MMHGR-2 Binds to but does not neutralize human interferon gamma receptor...
Recombinant Rat CINC-2 alpha, CF...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Biology Products: